Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate
Ontario and Arlington, Massachusetts--(Newsfile Corp. - March 18, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ: KALA) ("Kala Bio") today announced that Red Li
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-03-18 8:15 AM EDT | Red Light Holland Corp.
Optimi Health Announces Proposed Nasdaq Listing and U.S. Underwritten Public Offering
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced that it has commenced an underwritten public offering in the United States (the "Offering") of its common shares, no par value (the "Shares"), pursuant to a registration statement filed wi
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-03-16 7:00 AM EDT | Optimi Health Corp.
Numinus Wellness Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - March 13, 2026) - Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update. Corporate Update Over the past year, Numinus has undertaken a strategic transformation to streamline its operations and focus on its core
2026-03-13 5:00 PM EDT | Numinus Wellness Inc.
Psyched Wellness Announces Private Placement for Proceeds of up to C$1,719,306.94
Toronto, Ontario--(Newsfile Corp. - March 11, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is excited to announce that it has entered into a non-binding memorandum of terms (the "Term Sheet") with Gotham Green Fund III, L.P. and Gotham Green Fund III (Q), L.P. (together,
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2026-03-11 8:54 AM EDT | Psyched Wellness Ltd.
RETRANSMISSION: Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulation Combines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidate All-share t
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-03-11 7:30 AM EDT | Red Light Holland Corp.
Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulation Combines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidate All-share t
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-03-10 4:40 PM EDT | Red Light Holland Corp.
Numinus Wellness Advises of a Change of Auditor
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2026) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is advising of a change of its auditor. The Company's previous auditor, Horizon Assurance LLP ("Horizon") no longer serves as the Company's auditor, with PKF Antares Professional Corpora
2026-03-03 5:00 PM EST | Numinus Wellness Inc.
Red Light Holland Reports Third Quarter 2026 Results and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centered on consensual data collection and research and development ("R&D") initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experie
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2026-03-03 8:00 AM EST | Red Light Holland Corp.
Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today reported that patients diagnosed with treatment-resistant depression (TRD) have now been treated in Australia using the Company's naturally derived 5 mg psilocybin capsules under the Authorised Prescriber Scheme. The clinical a
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-26 7:00 AM EST | Optimi Health Corp.
Optimi Health berichtet über den frühen klinischen Einsatz natürlicher Psilocybin-Kapseln zur Behandlung therapieresistenter Depressionen in Australien
Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 26. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller pharmazeutischer Psychedelika-Produkte in pharmazeutischer Qualität, gab heute bekannt, dass in Australien nun Patienten mit therapieresistenter Depression (TRD) unter dem Authorised Prescriber Scheme mit den natürlich gewonnenen 5-mg-Psilocybin-Kapseln d
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-26 7:00 AM EST | Optimi Health Corp.
Neural Therapeutics Announces CSE Application to Acquire Full Ownership of Hanf.com, Shareholder Meeting, SIO Agreement Amendment and Concurrent Financing
Toronto, Ontario--(Newsfile Corp. - February 19, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has formally applied to the Canadian Securities Exchange (the "CSE") for approval to acquire the remaining 69.25% interest in CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers. Ronnie Jaegermann, Chief Executive Officer of CWE, stated: "Hanf.com h
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-19 8:53 AM EST | Neural Therapeutics Inc.
Optimi Health schließt Psilocybin-Export nach Australien zur Behandlung therapieresistenter Depression ab
Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 19. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller von psychedelischen Arzneimitteln in pharmazeutischer Qualität, gab heute den Export seiner nach GMP-Standards hergestellten natürlichen 5-mg-Psilocybin-Kapseln nach Australien bekannt. Diese werden zur Behandlung von Patientinnen und Patiente
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-19 2:00 AM EST | Optimi Health Corp.
Optimi Health Completes Psilocybin Export to Australia for Treatment Resistant Depression
Vancouver, British Columbia--(Newsfile Corp. - February 19, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today announced the export of its GMP-manufactured natural 5 mg psilocybin capsules to Australia for the treatment of patients diagnosed with treatment-resistant depression (TRD) under Australia's Authorised Prescriber Scheme.
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-19 2:00 AM EST | Optimi Health Corp.
Optimi Health Reports First MDMA-Assisted Treatments of 2026 are Underway Across an Expanded Network of Australian Clinics
Vancouver, British Columbia--(Newsfile Corp. - February 17, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that the first patients of 2026 have been treated using the Company's MDMA capsules at authorised clinics across Australia, operating under the Authorised Prescriber Scheme. The Company continues to supply its finished MDMA drug product d
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-17 7:00 AM EST | Optimi Health Corp.
Optimi Health meldet Beginn der ersten MDMA-gestützten Behandlungen im Jahr 2026 in einem erweiterten Netzwerk australischer Kliniken
Vancouver, British Columbia--(Newsfile Corp. - Montag, 16. Februar 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" oder das "Unternehmen"), ein von Health Canada lizenzierter Hersteller pharmazeutischer psychedelischer Arzneimittelprodukte, gab heute bekannt, dass die ersten Patientinnen und Patienten des Jahres 2026 in autorisierten Kliniken in ganz Australien mit den MDMA-Kapseln des Unternehmens behandelt wurden. Die Behandlungen erfolgen im Rahmen des Authorise
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-16 1:00 AM EST | Optimi Health Corp.
Neural Portfolio Company Hanf.com Reports Strong Fiscal 2025 Results with 58% Revenue Growth and Positive Normalized Operating Income
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to report preliminary unaudited financ
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-10 7:30 AM EST | Neural Therapeutics Inc.
Optimi Health Completes MDMA Export for PTSD Treatment Under Australia's Authorised Prescriber Scheme
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed its first export of MDMA capsules to Australia in 2026 under the Authorised Prescriber Scheme. The export included 1,000 of Optimi's MDMA capsules in a standardised 60 mg dosage form, supplied for use in authorised cl
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-02-09 7:00 AM EST | Optimi Health Corp.
Neural's Portfolio Company Hanf.com Announces Sales Start of Ritual Herbs Nicotine and Tobacco Free Products
Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CB
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-27 10:00 AM EST | Neural Therapeutics Inc.
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme. The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 n
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-26 7:00 AM EST | Optimi Health Corp.
Entheon Announces Execution of Business Combination Agreement with Nutravisor
Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into a definitive business combination agreement (the "Business Combination Agreement") with Nutravisor Inc. ("Nutravisor"), dated January 19, 2026, pursuant to which the parties have agreed to complete a business combination involving a "three-cornered" amalgamation of
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2026-01-19 5:28 PM EST | Entheon Biomedical Corp.